Among several small-molecule inhibitors of Survivin, including YM-155, HY-10194, Debio1143, EM1421, FL118, Flavokawain A, GDP366, LQZ-7I, LQZ-7F, and TL32711, emerging from preclinical studies, YM-155 (sepantronium bromide) has been extensively studied and shown to inhibit Survivin expression (at both the mRNA and protein levels with high potency and specificity) and tumor growth in a variety of human cancer xenograft models [21,22,23,24,25]. This evidence concerns the gene BIRC5 and cancer.